이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Atea Pharmaceuticals 과거 수익 실적

과거 기준 확인 0/6

Atea Pharmaceuticals의 수입은 연평균 -55.2%의 비율로 감소해 온 반면, Pharmaceuticals 산업은 수입이 연평균 0.2%의 비율로 감소했습니다. 매출은 연평균 99.3%의 비율로 감소해 왔습니다.

주요 정보

-55.2%

수익 성장률

-6.5%

EPS 성장률

Pharmaceuticals 산업 성장	6.0%
매출 성장률	-99.3%
자기자본 수익률	-36.9%
순이익	n/a
최근 수익 업데이트	30 Jun 2024

최근 과거 실적 업데이트

Recent updates

Analysts Just Shaved Their Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Forecasts Dramatically

Jan 05

Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Analysts Just Slashed Next Year's Estimates

Nov 25

A Look Into The Ownership Structure of Atea Pharmaceuticals (NASDAQ:AVIR)

Oct 24

A Look Into The Ownership Structure of Atea Pharmaceuticals (NASDAQ:AVIR)

Oct 24

Atea Pharmaceuticals' COVID Antiviral Trial Failure Hands Initiative To Merck's Molnupiravir

Oct 20

U.S. to invest more than $3B to boost development of COVID-19 antiviral drugs

Jun 17

Atea Pharmaceuticals, Inc. Beat Analyst Profit Forecasts, And Analysts Have New Estimates

May 15

Market Sentiment Around Loss-Making Atea Pharmaceuticals, Inc. (NASDAQ:AVIR)

May 13

Growth Investors: Industry Analysts Just Upgraded Their Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Revenue Forecasts By 73%

Apr 08

Atea Pharmaceuticals (NASDAQ:AVIR) Is In A Strong Position To Grow Its Business

Mar 06

Need To Know: Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Insiders Have Been Buying Shares

Jan 30

수익 및 비용 분석

Atea Pharmaceuticals 수익 창출 및 지출 방식. 최근 보고된 수익 기준, LTM 기준.

수익 및 매출 내역

NasdaqGS:AVIR 수익, 비용 및 수입 (USD Millions )
날짜	수익	수익	G+A 비용	R&D 비용
30 Jun 24	0	-176	49	0
31 Mar 24	0	-164	50	0
31 Dec 23	0	-136	50	0
30 Sep 23	0	-131	51	0
30 Jun 23	0	-106	50	0
31 Mar 23	0	-109	49	0
31 Dec 22	0	-116	49	0
30 Sep 22	192	36	50	0
30 Jun 22	225	16	50	0
31 Mar 22	285	48	50	0
31 Dec 21	351	121	46	0
30 Sep 21	208	25	47	0
30 Jun 21	175	35	39	0
31 Mar 21	115	24	29	0
31 Dec 20	49	-11	22	0
30 Sep 20	0	-36	9	-7
30 Jun 20	0	-22	6	-4
31 Mar 20	0	-16	5	-1
31 Dec 19	0	-14	4	0

양질의 수익: AVIR 은(는) 현재 수익성이 없습니다.

이익 마진 증가: AVIR 은(는) 현재 수익성이 없습니다.

잉여현금흐름 대 수익 분석

과거 수익 성장 분석

수익추이: AVIR 은(는) 수익성이 없으며 지난 5년 동안 연간 54.1% 비율로 손실이 증가했습니다.

성장 가속화: 현재 수익성이 없기 때문에 AVIR 의 지난 1년 동안의 수익 성장을 5년 평균과 비교할 수 없습니다.

수익 대 산업: AVIR 은(는) 수익성이 없어 지난 해 수익 성장을 Pharmaceuticals 업계( 13% )와 비교하기 어렵습니다.

자기자본 수익률

높은 ROE: AVIR 현재 수익성이 없기 때문에 마이너스 자본 수익률( -36.94% )을 갖습니다.

Atea Pharmaceuticals 과거 수익 실적

과거 기준 확인 0/6

주요 정보

최근 과거 실적 업데이트

Atea Pharmaceuticals, Inc. to Report Q3, 2023 Results on Nov 08, 2023

Third quarter 2022 earnings released: US$0.097 loss per share (vs US$0.34 loss in 3Q 2021)

First half 2022 earnings released

Full year 2021 earnings: EPS and revenues exceed analyst expectations

Recent updates

Founder notifies of intention to sell stock

Atea Pharmaceuticals Provides Update on Global Phase 3 Rise-3 Trial Evaluating Bemnifosbuvir for Treatment of COVID-19

Independent Director recently sold US$61k worth of stock

Price target increased by 18% to US$5.50

Atea Pharmaceuticals Presents Positive Initial Phase 2 Data for Bemnifosbuvir and Ruzasvir Combination for Treatment of Hepatitis C Virus at EASL Congress 2024

Atea Pharmaceuticals Presents New Data Showcasing Potential Best-in-Class Combination Profile of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus at EASL Congress 2024

Atea Pharmaceuticals, Inc., Annual General Meeting, Jun 21, 2024

Atea Pharmaceuticals, Inc. Completes Patient Enrollment in Global Phase 3 Sunrise-3 Trial Evaluating Oral Antiviral Bemnifosbuvir for COVID-19 in High-Risk Patients

Founder notifies of intention to sell stock

Atea Pharmaceuticals, Inc. Announces Positive Initial Data from Phase 2 Study for Hepatitis C Virus (HCV) and Significant Enrollment for Phase 3 SUNRISE-3 Trial for COVID-19

Price target decreased by 15% to US$5.33

Atea Pharmaceuticals, Inc. to Present Bemnifosbuvir and Ruzasvir Data for the Treatment of Hepatitis C Virus at AASLD the Liver Meeting 2023

Atea Pharmaceuticals, Inc. to Report Q3, 2023 Results on Nov 08, 2023

Insufficient new directors

Atea Pharmaceuticals, Inc.(NasdaqGS:AVIR) dropped from Russell 2000 Defensive Index

Atea Pharmaceuticals, Inc. Announces First Patient Dosed in Phase 2 Study for Treatment of Hepatitis C with Bemnifosbuvir and Ruzasvir Combination

Concentra Biosciences, LLC cancelled the acquisition of 96.37% stake in Atea Pharmaceuticals, Inc. (NasdaqGS:AVIR).

Concentra Biosciences, LLC submitted a non-binding proposal to acquire 96.37% stake in Atea Pharmaceuticals, Inc. (NasdaqGS:AVIR) for approximately $480 million.

Investor sentiment deteriorates as stock falls 16%

Price target decreased to US$9.00

Atea Pharmaceuticals, Inc. Provides an Update on the Clinical Development Programs for 2023

Atea Pharmaceuticals, Inc. Announces First Patient Dosed in SUNRISE-3 Phase 3 Registrational Trial of Bemnifosbuvir, an Investigational Oral Antiviral for the Treatment of COVID-19

Lead Independent Director notifies of intention to sell stock

Lead Independent Director recently sold US$215k worth of stock

Third quarter 2022 earnings released: US$0.097 loss per share (vs US$0.34 loss in 3Q 2021)

Atea Pharmaceuticals, Inc. Announces U.S. FDA Fast Track Designation Granted to AT-752 for Treatment of Dengue

Atea wins FDA Fast Track status for dengue treatment

Investor sentiment deteriorated over the past week

Atea Pharmaceuticals, Inc. to Advance Global Phase 3 Registrational Study of Bemnifosbuvir in High-Risk Non-Hospitalized Patients with COVID-19

Consensus forecasts updated

First half 2022 earnings released

Atea Pharmaceuticals Q2 2022 Earnings Preview

Atea Pharmaceuticals, Inc.(NasdaqGS:AVIR) dropped from Russell 2000 Growth Index

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Atea Pharmaceuticals, Inc.'s (NASDAQ:AVIR) Shares Not Telling The Full Story

Atea Pharmaceuticals, Inc., Annual General Meeting, Jun 17, 2022

Price target decreased to US$10.50

Investor sentiment improved over the past week

Full year 2021 earnings: EPS and revenues exceed analyst expectations

Price target decreased to US$11.67

Atea Pharmaceuticals, Inc. Announces Executive Changes

Investor sentiment deteriorated over the past week

Price target decreased to US$15.50

Consensus EPS estimates increase by 131%

Analysts Just Shaved Their Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Forecasts Dramatically

Independent Director recently bought US$103k worth of stock

Consensus forecasts updated

Atea Pharmaceuticals Introduces New Strategic Clinical Development Program for AT-527 in Covid-19

Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Analysts Just Slashed Next Year's Estimates

Investor sentiment deteriorated over the past week

Price target decreased to US$16.25

A Look Into The Ownership Structure of Atea Pharmaceuticals (NASDAQ:AVIR)

A Look Into The Ownership Structure of Atea Pharmaceuticals (NASDAQ:AVIR)

Atea Pharmaceuticals' COVID Antiviral Trial Failure Hands Initiative To Merck's Molnupiravir

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Atea Pharmaceuticals Announces Publication of Data Highlighting AT-752’s Potent In Vitro and In Vivo Activity Against Dengue and Other Flaviviruses

Consensus EPS estimates increase to US$0.62

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Atea Pharmaceuticals, Inc. Announces Positive Interim Results from the Global Phase 2 Study Evaluating AT-527

Independent Director Andrew A. Hack has left the company

Independent Director Andrew A. Hack has left the company

Atea Pharmaceuticals Announces Achievement of AT-527 Development Milestone Under License Agreement with Roche

U.S. to invest more than $3B to boost development of COVID-19 antiviral drugs

Investor sentiment improved over the past week

Consensus revenue estimates increase to US$1.70b

Investor sentiment improved over the past week

Consensus forecasts updated

Atea Pharmaceuticals, Inc. Beat Analyst Profit Forecasts, And Analysts Have New Estimates